Individualizing Treatment for Asthma in Primary Care (Full Study)
Status:
NOT_YET_RECRUITING
Trial end date:
2029-11-15
Target enrollment:
Participant gender:
Summary
While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. Inhaled corticosteroid (ICS) medications are the foundation of care for all individuals with persistent asthma. But ICS use is not without possible long term side effects.
This study will compare two currently available approaches to reduce AEX in primary care patients: (1) use of inhaled corticosteroids (ICS) as part of rescue therapy, also known as MART (Maintenance And Reliever Therapy) or PARTICS (Patient Activated Reliever Trigger Inhaled Corticosteriods) therapy - either of these therapies will be called Rescue-Inhaled Corticosteroids or R-ICS pronounced "Ricks," and (2) use of azithromycin (AZ) as a preventive therapy. These treatments will be studied both individually and in combination.
Phase:
PHASE4
Details
Lead Sponsor:
DARTNet Institute
Collaborators:
AdventHealth Icahn School of Medicine at Mount Sinai John Peter Smith Health Network Kelsey Research Foundation Penn State University RAND Reliant Medical Group Rutgers University University of Colorado, Denver University of Kansas University of Missouri-Columbia University of North Carolina University of Washington Wake Forest University Health Sciences